Research on experimental hyperlipemia. 3. Action "in vivo" of the inhibitor of the clarifying factor
Tayeau, F.; Jouzier, E.; Tixier, M.
Bordeaux Medical 3(9): 2011-2014
1970
ISSN/ISBN: 0021-7867 PMID: 5481184 Document Number: 18414
Document emailed within 1 workday
Related Documents
Tayeau, F.; Jouzier, E.; Tixier, M. 1970: Research on experimental hyperlipemia. II. Isolation and "in vitro" study of a natural inhibitor of the clarifying factor Bordeaux Medical 3(9): 1999-2008Secchi, A.G.; Carli, A. 1971: Action of a proteinase inhibitor in experimental uveitis Annali di Ottalmologia E Clinica Oculistica 97(2): 41-46
Nagase, H.; Enjyoji, K.; Kamikubo, Y.; Kitazato, K.T.; Kitazato, K.; Saito, H.; Kato, H. 1997: Effect of depolymerized holothurian glycosaminoglycan (DHG) on tissue factor pathway inhibitor: in vitro and in vivo studies Thrombosis and Haemostasis 78(2): 864-870
Buc, M.; Siska, P.; Rovenský, J.; Pruzinec, P.; Stefanovic, J.; Pekárek, J.; Svejcar, J. 1982: Changes in T-lymphocyte response under the action of transfer factor in vivo Bratislavske Lekarske Listy 78(1): 63-73
Vairel, E.G.; Hureau, J. 1973: Study of the mode of action of Kunitz inhibitor in kaolin experimental shock and comparison with some chemical derivatives used in therapeutics Annales Pharmaceutiques Francaises 31(6): 409-414
Ray, S 1997: Prevention of HIV/STI transmission: clarifying the research questions Reproductive Health Matters 5(10): 154-155
Kozai, T.; Shimokawa, H.; Fukumoto, Y.; Kobayashi, S.; Owada, M.K.; Kadokami, T.; Ito, A.; Kuwata, K.; Egashira, K.; Shiraishi, T.; Kanaide, H.; Takeshita, A. 1997: Tyrosine kinase inhibitor markedly suppresses the development of coronary lesions induced by long-term treatment with platelet-derived growth factor in pigs in vivo Journal of Cardiovascular Pharmacology 29(4): 536-545
Messer, M. 2016: Clarifying the goals of the research and selecting information sources Pflege Zeitschrift 69(5): 300
Holst, J.; Lindblad, B.; Matthíasson, S.E.; Stjernquist, U.; Ezban, M.; Ostergaard, P.B.; Hedner, U. 1996: Experimental haemorrhagic effect of two-domain non-glycosylated tissue factor pathway inhibitor compared to low molecular weight heparin Thrombosis and Haemostasis 75(4): 585-589
Beyaert, R.; Vanhaesebroeck, B.; Heyninck, K.; Boone, E.; De Valck, D.; Schulze-Osthoff, K.; Haegeman, G.; Van Roy, F.; Fiers, W. 1993: Sensitization of tumor cells to tumor necrosis factor action by the protein kinase inhibitor staurosporine Cancer Research 53(11): 2623-2630
Takeuchi, N. 1972: Experimental hyperlipemia Nihon Rinsho. Japanese Journal of Clinical Medicine 30(1): 347-350
Yamazaki, M.; Asakura, H.; Aoshima, K.; Saito, M.; Jokaji, H.; Uotani, C.; Kumabashiri, I.; Morishita, E.; Ikeda, T.; Matsuda, T. 1994: Effects of DX-9065a, an orally active, newly synthesized and specific inhibitor of factor Xa, against experimental disseminated intravascular coagulation in rats Thrombosis and Haemostasis 72(3): 392-396
Wang, S.-m.; Zhu, Y.-f.; Wang, J.-s. 2004: PCKM-mPTH recombinant plasmid therapy for hypoparathyroidism: an in vivo experimental research with rats Zhonghua Yi Xue Za Zhi 84(24): 2107-2109
Valueva, G.V.; Slavnov, V.N.; Luchitskiĭ, E.V.; Markov, V.V.; Iakovlev, A.A. 1988: Experimental and clinical research on the action of parlodel on body endocrine functions Patologicheskaia Fiziologiia i Eksperimental'naia Terapiia 3: 38-41
Ziabbarova, S.A.; Kuklina, M.N.; Iakovleva, L.E. 1974: Some experimental data on a study of the biological action of ethylbutylamine as a factor in the pollution in reservoirs Gigiena i Sanitariia 39(3): 106-107
Aufiero, C.; Corsini, G.; De Felice, D.; De Franciscis, P.; De Vivo, P.; Renda, G.; Scapicchio, A. 1970: Action of the splenic factor in experimental cardiac insufficiency induced with volume overloading Bollettino della Societa Italiana di Biologia Sperimentale 46(17): 699-702
Gries, F.A. 1975: Risk factor hyperlipemia: clinical aspects and therapy Die Medizinische Welt 26(36): 1590-1597
Hashimoto, T.; Kobayashi, M.; Igarashi, H.; Niitani, H. 1975: Hyperlipemia as a risk factor in ischemic heart disease Nihon Rinsho. Japanese Journal of Clinical Medicine 33(11): 3179-3184
Della Porta, P.; Soeltl, R.; Krell, H.W.; Collins, K.; O'Donoghue, M.; Schmitt, M.; Krüger, A. 1999: Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor Batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells in vivo Anticancer Research 19(5b): 3809-3816
Rémy, A.; Avouac, J.; Gossec, L.; Combe, B. 2011: Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis Clinical and Experimental Rheumatology 29(1): 96-103